These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 25961376)

  • 1. Rational combination of MEK inhibitor and the STAT3 pathway modulator for the therapy in K-Ras mutated pancreatic and colon cancer cells.
    Zhao C; Xiao H; Wu X; Li C; Liang G; Yang S; Lin J
    Oncotarget; 2015 Jun; 6(16):14472-87. PubMed ID: 25961376
    [TBL] [Abstract][Full Text] [Related]  

  • 2. KRAS mutant lung cancer cells are differentially responsive to MEK inhibitor due to AKT or STAT3 activation: implication for combinatorial approach.
    Yoon YK; Kim HP; Han SW; Oh DY; Im SA; Bang YJ; Kim TY
    Mol Carcinog; 2010 Apr; 49(4):353-62. PubMed ID: 20358631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of MEK Inhibitor and the JAK2-STAT3 Pathway Inhibition for the Therapy of Colon Cancer.
    Jin J; Guo Q; Xie J; Jin D; Zhu Y
    Pathol Oncol Res; 2019 Apr; 25(2):769-775. PubMed ID: 30706361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines.
    Ulivi P; Arienti C; Amadori D; Fabbri F; Carloni S; Tesei A; Vannini I; Silvestrini R; Zoli W
    J Cell Physiol; 2009 Jul; 220(1):214-21. PubMed ID: 19288493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inverse Correlation of STAT3 and MEK Signaling Mediates Resistance to RAS Pathway Inhibition in Pancreatic Cancer.
    Nagathihalli NS; Castellanos JA; Lamichhane P; Messaggio F; Shi C; Dai X; Rai P; Chen X; VanSaun MN; Merchant NB
    Cancer Res; 2018 Nov; 78(21):6235-6246. PubMed ID: 30154150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toll-like receptor 9 agonist IMO cooperates with cetuximab in K-ras mutant colorectal and pancreatic cancers.
    Rosa R; Melisi D; Damiano V; Bianco R; Garofalo S; Gelardi T; Agrawal S; Di Nicolantonio F; Scarpa A; Bardelli A; Tortora G
    Clin Cancer Res; 2011 Oct; 17(20):6531-41. PubMed ID: 21890455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The HSP90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant non-small cell lung cancer with intrinsic resistance to MEK inhibitor, trametinib.
    Park KS; Oh B; Lee MH; Nam KY; Jin HR; Yang H; Choi J; Kim SW; Lee DH
    Cancer Lett; 2016 Mar; 372(1):75-81. PubMed ID: 26723875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination therapy targeting Raf-1 and MEK causes apoptosis of HCT116 colon cancer cells.
    Subramanian RR; Yamakawa A
    Int J Oncol; 2012 Nov; 41(5):1855-62. PubMed ID: 22922669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Physapubescin B enhances the sensitivity of gastric cancer cells to trametinib by inhibiting the STAT3 signaling pathway.
    Dai C; Shen L; Jin W; Lv B; Liu P; Wang X; Yin Y; Fu Y; Liang L; Ma Z; Zhang X; Wang Y; Xu D; Chen Z
    Toxicol Appl Pharmacol; 2020 Dec; 408():115273. PubMed ID: 33035574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular subtype specific efficacy of MEK inhibitors in pancreatic cancers.
    Brauswetter D; Gurbi B; Varga A; Várkondi E; Schwab R; Bánhegyi G; Fábián O; Kéri G; Vályi-Nagy I; Peták I
    PLoS One; 2017; 12(9):e0185687. PubMed ID: 28957417
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas.
    Migliardi G; Sassi F; Torti D; Galimi F; Zanella ER; Buscarino M; Ribero D; Muratore A; Massucco P; Pisacane A; Risio M; Capussotti L; Marsoni S; Di Nicolantonio F; Bardelli A; Comoglio PM; Trusolino L; Bertotti A
    Clin Cancer Res; 2012 May; 18(9):2515-25. PubMed ID: 22392911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Growth factor-dependent activation of the Ras-Raf-MEK-MAPK pathway in the human pancreatic carcinoma cell line PANC-1 carrying activated K-ras: implications for cell proliferation and cell migration.
    Giehl K; Skripczynski B; Mansard A; Menke A; Gierschik P
    Oncogene; 2000 Jun; 19(25):2930-42. PubMed ID: 10871844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. STAT3 mediates resistance to MEK inhibitor through microRNA miR-17.
    Dai B; Meng J; Peyton M; Girard L; Bornmann WG; Ji L; Minna JD; Fang B; Roth JA
    Cancer Res; 2011 May; 71(10):3658-68. PubMed ID: 21444672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the Janus-activated kinase-2-STAT3 signalling pathway in pancreatic cancer using the HSP90 inhibitor ganetespib.
    Nagaraju GP; Mezina A; Shaib WL; Landry J; El-Rayes BF
    Eur J Cancer; 2016 Jan; 52():109-19. PubMed ID: 26682870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MEK inhibitor enhances the inhibitory effect of imatinib on pancreatic cancer cell growth.
    Takayama Y; Kokuryo T; Yokoyama Y; Nagino M; Nimura Y; Senga T; Hamaguchi M
    Cancer Lett; 2008 Jun; 264(2):241-9. PubMed ID: 18346844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition.
    Gilmartin AG; Bleam MR; Groy A; Moss KG; Minthorn EA; Kulkarni SG; Rominger CM; Erskine S; Fisher KE; Yang J; Zappacosta F; Annan R; Sutton D; Laquerre SG
    Clin Cancer Res; 2011 Mar; 17(5):989-1000. PubMed ID: 21245089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rational application of targeted therapeutics in mucinous colon/appendix cancers with positive predictive factors.
    Dilly A; Honick BD; Lee YJ; Bartlett DL; Choudry HA
    Cancer Med; 2020 Mar; 9(5):1753-1767. PubMed ID: 31958897
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel Ras inhibitor (MDC-1016) reduces human pancreatic tumor growth in mice.
    Mackenzie GG; Bartels LE; Xie G; Papayannis I; Alston N; Vrankova K; Ouyang N; Rigas B
    Neoplasia; 2013 Oct; 15(10):1184-95. PubMed ID: 24204197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aphanin, a triterpenoid from Amoora rohituka inhibits K-Ras mutant activity and STAT3 in pancreatic carcinoma cells.
    Rabi T; Catapano CV
    Tumour Biol; 2016 Sep; 37(9):12455-12464. PubMed ID: 27333990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel small molecule STAT3 inhibitor, LY5, inhibits cell viability, colony formation, and migration of colon and liver cancer cells.
    Zhao C; Wang W; Yu W; Jou D; Wang Y; Ma H; Xiao H; Qin H; Zhang C; Lü J; Li S; Li C; Lin J; Lin L
    Oncotarget; 2016 Mar; 7(11):12917-26. PubMed ID: 26883202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.